Get the latest news, insights, and market updates on BCS (Barclays PLC). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Should Value Investors Buy Barclays (BCS) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. Feb 16, 2026 - $BCS
Barclays’ £15b Returns And AI Push Put Valuation In Focus
Barclays (LSE:BARC) has set out a plan to return more than £15b to shareholders between 2026 and 2028 through dividends and share buybacks. The announcement follows record 2025 financial results, with the bank reporting that it met and exceeded all its stated 2025 financial targets. Barclays is also rolling out extensive artificial intelligence initiatives aimed at cost efficiency and income growth across its business. For you as an investor, this is a high impact update from one of the... Feb 14, 2026 - $BCS
Assessing Barclays (LSE:BARC) Valuation After Recent Share Price Weakness
Barclays share performance snapshot With no single headline event driving Barclays (LSE:BARC) today, recent share performance and fundamentals offer useful context. The stock shows a 2.1% decline over the past day and a 5.2% decline over the past week. See our latest analysis for Barclays. Looking beyond this week, Barclays has a 30 day share price return of a 5.4% decline, a 90 day share price return of 9.8% and a 1 year total shareholder return of 58.2%. Short term momentum has cooled... Feb 14, 2026 - $BCS
Bank boss pay surges after bumper profits at Lloyds, Barclays and NatWest
The UK's biggest banks have had a strong annual earnings season. Updates from Barclays, Lloyds and NatWest have shown strong profit growth, with their respective UK earnings being boosted by the slower-than-hoped-for pace of interest rate cuts introduced by the Bank of England last year. Cost-cutting has played a role too, with lenders eyeing up big opportunities for artificial intelligence (AI) to boost functionality and cut employment bills at the same time. Feb 13, 2026 - $BCS
Vertex Pharma (VRTX) Renal Pipeline Seen as Major Growth Driver by Barclays
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ranks among the best high growth high margin stocks to buy now. On January 28, Barclays began coverage of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) with an Overweight rating and a $606 price target, voicing confidence about Vertex’s renal franchise, implying that it might achieve significant market attention in 2026 and perhaps follow […] Feb 13, 2026 - $BCS
Umicore - Transparency notification by Barclays PLC
Transparency notification by Barclays PLC In accordance with article 14, § 1 of the law of 2 May 2007 on the disclosure of major holdings, Umicore was recently notified by Barclays PLC that it has crossed the legal threshold of 3% for the direct voting rights and equivalent financial instruments upwards on 2 February 2026. The total holding of direct voting rights and equivalent financial instruments of Barclays PLC stands at 3.22% on 2 February 2026. Summary of the move by Barclays PLC: Date on Feb 13, 2026 - $BCS
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple